Stock Price, News, Quote and Profile of OPIANT PHARMACEUTICALS INC(NASDAQ:OPNT) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

OPIANT PHARMACEUTICALS INC

NASDAQ:OPNT (3/1/2023, 7:00:03 PM)

After market: 20.75 +0.1 (+0.48%)

20.65

-0.12 (-0.58%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryPharmaceuticals

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap108.80M

PEN/A

Fwd PEN/A

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 37 full-time employees. The company went IPO on 2017-09-18. The firm developed NARCAN (naloxone hydrochloride) Nasal Spray (NARCAN), a treatment to reverse opioid overdose. The firm's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), and Acute Cannabinoid Overdose (ACO). The firm is also pursuing other treatment opportunities within the addiction and drug overdose field. Its lead development product is OPNT003 a nasal nalmefene for the treatment of opioid overdose.

Company Info

OPIANT PHARMACEUTICALS INC

233 Wilshire Blvd, Suite 400

Santa Monica CALIFORNIA 90401

P: 13105985410.0

CEO: Roger Crystal

Employees: 37

Website: https://www.opiant.com/

OPNT News

a year ago - Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC

CFIUS clearance represents the final required regulatory approval to complete the proposed mergerCompletion remains subject to the approval of Opiant...

a year ago - Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC

SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period...

a year ago - Seeking AlphaHorizon, Opiant stock fall on report Elizabeth Warren concerned about pharma deals

Horizon Pharmaceuticals (HZNP) dropped on a report that Sen. Elizabeth Warrenhas concerns about Amgen's (AMGN) plan to buy Horizon Therapeutics (HZNP) and Indivior plan to acquire Opiant

a year ago - Seeking AlphaHorizon, Opiant stock fall amid Elizabeth Warren concerned about pharma deals

Horizon Pharmaceuticals (HZNP) dropped on a report that Sen. Elizabeth Warrenhas concerns about Amgens (AMGN) plan to buy Horizon Therapeutics (HZNP) and Indivior plan to acquire Opiant

OPIANT PHARMACEUTICALS INC (OPNT)

Nasdaq Stock Screener

USA Stock Screener